George Scangos, Vir CEO (BIO via YouTube)
As GSK-partnered Covid antibody racks up global sales, Vir axes WuXi deal and grabs back China rights
Early on in the Covid-19 pandemic, Vir Biotechnology enlisted China’s powerhouse CDMO WuXi Biologics for cell line development, process and formulation development as well as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.